

Presidency handover at Werfen, world leader in *in vitro* diagnostics⁽¹⁾

- **Jordi Rubiralta assumes the presidency of the Family Council and leaves role as President of Werfen**
- **Marc Rubiralta assumes role as President of Werfen, effective January 1, 2019**
- **Werfen is a world leader in the areas of Hemostasis⁽²⁾, Acute Care⁽³⁾ and Autoimmunity⁽⁴⁾**

Barcelona, December 17, 2018. - Since Werfen was founded, more than 50 years ago, the Rubiralta family has always been fully committed to its growth and future. In January 2012, Jordi Rubiralta was appointed President of the company and, following the death of Werfen founder, José Maria Rubiralta, ownership of the company passed to the four Rubiralta Giralt brothers and, therefore, the next generation. The family-run business has continued to enjoy positive results and excellent performance, and the family's other economic and social activities have also experienced continued growth. All of these activities have been coordinated and directed by the Family Council, a body that is becoming increasingly important as the main decision-maker across the family enterprises.

With the aim of better managing both Werfen and the Family Council, and in full unanimous agreement, the four brothers have decided to implement the following organizational changes:

- A new position, President of the Family Council, has been created, and Jordi Rubiralta Giralt will assume this role from January 1, 2019. His function will be to coordinate the business activities, including social projects and property investments of the four Rubiralta Giralt brothers. In order to assume this new and demanding responsibility, he will leave his current position as President of Werfen and focus on the transfer of knowledge and professional experience to the rest of the family initiatives. During his tenure, Jordi Rubiralta's key successes include reinforcing the position of Werfen as a global leader through commercial expansion in the United States and China, and fostering significant professionalization within the company. Other milestones include celebrating the 50th Anniversary of the company, the acquisitions of Tem, an expert company in viscoelastic technology for blood transfusion management, and Accriva Diagnostics, a leader in point-of-care⁽⁵⁾ for hemostasis in operating theaters and intensive care, and significant investment in the new Biokit technology center in Barcelona.

- Marc Rubiralta Giralt will be appointed President of Werfen on January 1, 2019. Marc holds a degree in Business Administration and Management from ESADE, and has previously worked at Deloitte, and for Werfen in Spain and China as Chief Financial Officer. For the last four years, he has been Chairman of the Medical Devices division and a member of the Executive Committee, the top governance body within Werfen.

These changes are aligned with the long-term view, commitment and determination that the four brothers have for Werfen, and the other economic and social activities of the family.

As we approach the close of this financial year, Werfen is again poised to post positive results and growth. The process of integrating the latest acquisitions from 2016 and 2017 is now complete and expectations continue favorable.

WERFEN

Werfen is a global leader in the IVD field, specializing in the areas of Hemostasis and Acute Care Diagnostics through its company *Instrumentation Laboratory*, including its recently acquired companies of *Tem* (viscoelastic technology for blood transfusion management) and *Accriva Diagnostics* (point-of-care for hemostasis in operating theaters and intensive care), as well as in Autoimmunity through its company *Inova Diagnostics*. Werfen also manufactures reagents⁽⁶⁾ and biomaterials⁽⁷⁾ for third parties and offers solutions in the area of infectious disease serology through its company *Biokit*. Its other areas of focus within IVD include clinical software and clinical chemistry. Every day, laboratories around the world use Werfen reagents and systems to test more than 1.5 million samples for the benefit of patients.

Werfen is also involved in medical devices through its company *Leventon*, which specializes in Infusion Therapy⁽⁸⁾. In addition, Werfen distributes medical devices and scientific instrumentation in Spain and Portugal through the companies *Izasa Hospital* and *Izasa Scientific*, and in further European countries via other own companies.

(1) *In Vitro* Diagnostics (IVD): Non-invasive tests performed on biological samples such as blood, urine, or tissue, to diagnose, monitor, or rule out a disease.

(2) *Hemostasis*: The balance of the interaction between blood coagulation proteins, platelets and the vessel walls, which maintains blood flow.

(3) *Acute Care Diagnostics*: The specialized treatment of life-threatening conditions requiring rapid, comprehensive patient care and frequent monitoring - usually in intensive care units, emergency rooms, and operating theaters.

(4) *Autoimmunity*: Autoimmunity occurs when the body's immune system fails to recognize itself, resulting in antibodies being directed against the body's own tissues (autoantibodies). Autoimmune diseases are caused by autoantibodies and include rheumatoid arthritis, systemic lupus erythematosus, celiac disease, Crohn's disease, and many other diseases.

(5) *Point-of-care testing (POCT)*: Point-of-care testing is defined as medical diagnostic testing at or near the point of patient care.

(6) *Reagents*: A substance or a compound added to a system to cause a chemical reaction. Reagents are often used to indicate the presence of another substance.

(7) *Biomaterials*: Biomaterials are any substances of biological origin (usually proteins) that have been designed, produced and purified to function as the main raw material on an IVD test.

(8) *Infusion Therapy*: Infusion therapy refers to delivering medication into a vein through a needle or a catheter.

Legal notice

This document contains forward-looking statements about our business, financial data, and events related to the prospects of Werfen. These forecasts can be identified by the use of words such as "expectation", "vision", "anticipation", "intention", "plan", "belief", "search", "estimate", "future", "project" or words with a similar meaning. We may also make projections in other reports, presentations, and press releases. Furthermore, our sales representatives may occasionally make forward-looking statements. These projections are based on our current expectations and on certain hypotheses, many of which are beyond the corporation's control and are subject to a series of risks and uncertainties. In the event that any of these risks or uncertainties should materialize or the underlying expectations are not fulfilled, the results or performance of Werfen may differ substantially (either positively or negatively) from those expressly or implicitly forecast. Werfen assumes no obligation to update or revise any forward-looking statements made previously.

Media contact:**Werfen**

Gloria Maltas

Corporate Image & Communications Manager

Tel. +34 93-401-01-01

gmaltas@werfen.com

Atrevia

Communication Agency

Alberto Valle

Tel. +34 93-419-06-30

avalle@atrevia.com